Опубликована: Янв. 1, 2024
Язык: Английский
Medical Oncology, Год журнала: 2025, Номер 42(3)
Опубликована: Фев. 3, 2025
Natural drugs have the advantages of multi-pathway, multi-target, low toxicity, and high efficiency, which make them widely used effective in anti-tumor therapy. Dioscin is a steroidal saponin compound that can be extracted from Dioscaceae plants. In recent years, it has been found potent effects, inhibit tumor cell proliferation, induce apoptosis autophagy, inhibits metastasis, reverses multidrug resistance, increases sensitivity to anticancer drugs, thus progression. Meanwhile, construction nanocarriers improve efficiency drug use, reduce realize precise delivery bioavailability Dioscin. this paper, mechanism targets years were reviewed, thereby providing new ideas theoretical basis for further research promotion
Язык: Английский
Процитировано
0
The American Journal of Chinese Medicine, Год журнала: 2025, Номер unknown, С. 1 - 23
Опубликована: Март 27, 2025
Non-small cell lung cancer (NSCLC) is a malignancy that faces serious resistance challenges in treatment. In this study, we identified Piperlongumine as promising therapeutic candidate to overcome Osimertinib NSCLC. We systematically investigated the inhibitory effect of on NSCLC cells and confirmed it could effectively inhibit vitro kinase activity wild-type (WT), exon 19 deletion, L858R/T790M-mutated EGFR. also found Piperlongumine-induced intrinsic apoptosis by interfering with EGFR signaling pathway, which was characterized down-regulation anti-apoptotic protein Mcl-1. Further mechanistic studies revealed degradation Mcl-1 dependent Akt-GSK3[Formula: see text] pathway. Additionally, Piperlongumine-promoted interaction between [Formula: text]-TRCP, thereby enhancing text]-TRCP-mediated ubiquitination Furthermore, significantly inhibited tumor growth both Osimertinib-sensitive resistant xenograft models. These findings highlight potential an effective agent overcoming EGFR-targeted therapy suggest new avenues for its clinical application
Язык: Английский
Процитировано
0
Cell Death Discovery, Год журнала: 2025, Номер 11(1)
Опубликована: Апрель 7, 2025
Язык: Английский
Процитировано
0
Bioorganic Chemistry, Год журнала: 2024, Номер 154, С. 108038 - 108038
Опубликована: Дек. 6, 2024
Язык: Английский
Процитировано
2
Cell Death Discovery, Год журнала: 2024, Номер 10(1)
Опубликована: Окт. 28, 2024
Abstract Non-small cell lung cancer (NSCLC) is a prevalent and fatal malignancy with significant global impact. Recent advancements have introduced targeted therapies like tyrosine kinase inhibitors (TKIs) such as osimertinib, which improved patient outcomes, particularly in those EGFR mutations. Despite these advancements, acquired resistance to TKIs remains challenge. Hence, one of the current research priorities understanding mechanisms identifying new therapeutic targets improve efficacy. Herein, we identified high expression c-Met osimertinib-resistant NSCLC cells, depletion significantly inhibited proliferation cells prolonged survival mice, suggesting an attractive target. To identify effective anti-tumor agents targeting c-Met, screened compound library containing 641 natural products found that only xanthohumol exhibited potent inhibitory effects against cells. Moreover, combination treatment osimertinib sensitized both vitro vivo. Mechanistically, disrupted interaction between USP9X Ets-1, phosphorylation Ets-1 at Thr38, promoting its degradation, thereby Ets-1/c-Met signaling axis inducing intrinsic apoptosis Overall, highlights critical role address NSCLC. By demonstrating efficacy overcoming enhancing this study provides valuable insights potential strategies for improving clinical management
Язык: Английский
Процитировано
1
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
0